The goal of this program is to improve management of early breast cancer (BC) with cyclin-dependent kinase (CDK) inhibitors. After hearing and assimilating this program, the clinician will be better able to: 1. Mitigate the risk for venous thromboembolism associated with abemaciclib in patients with high-risk, node-positive, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative BC. 2. Analyze the clinical benefits of adjuvant ribociclib for patients with high-risk, ER-positive, HER2-negative BC.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2024-09-26 05:00:00
- End Date: 2024-09-26 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest